PDLIM7

PDLIM7 (Enigma) is a multifunctional PDZ-LIM domain scaffold protein that couples cytoskeletal organization, receptor tyrosine kinase signaling, and transcription factor trafficking to regulate cell differentiation, cardiac morphogenesis, and inflammatory responses. It anchors Ret/ptc2 to the cell periphery to enable mitogenic signaling (PMID:9528800), organizes the actin cytoskeleton through interactions with PKC and the adaptor APS (PMID:8940095, PMID:15946664), and controls nuclear–cytoplasmic shuttling of Tbx5 and YAP1 to regulate cardiac valve specification and prostate cancer growth, respectively (PMID:19895804, PMID:36823643). PDLIM7 also functions as an E3 ubiquitin ligase that polyubiquitinates the NF-κB subunit p65 and cooperates with PDLIM2 and p62/SQSTM1 to deliver it for proteasomal degradation, suppressing inflammatory signaling (PMID:32849529). In vivo, loss of Pdlim7 causes cardiac valve defects, thrombosis, and loss of vascular smooth muscle cell differentiation, establishing its requirement for cardiovascular homeostasis and hemostasis (PMID:24278323, PMID:27470516).

1. 1996 Medium

   Identifying PDLIM7's first signaling partner established that its LIM domains serve as a docking site for kinases, raising the question of how this scaffold integrates into signaling networks.

   Evidence Yeast two-hybrid, co-IP in COS-7 cells, and in vitro kinase assay showing PKC binds and phosphorylates Enigma

   PMID:8940095

   Open questions at the time

   • Functional consequence of PKC phosphorylation of PDLIM7 in cells not determined
   • No in vivo validation of the PKC–PDLIM7 axis
2. 1998 High

   Demonstrating that PDLIM7 localizes Ret/ptc2 to the cell periphery and is required for its mitogenic activity revealed PDLIM7 as a spatial organizer of receptor tyrosine kinase signaling.

   Evidence Co-IP, dominant-negative Ras/Raf epistasis, subcellular localization, and chimeric protein assays in cultured cells

   PMID:9528800

   Open questions at the time

   • Whether PDLIM7 scaffolds other RTKs beyond Ret/ptc2 was unexplored
   • Downstream effectors of PDLIM7-localized Ret signaling not mapped
3. 2005 Medium

   Showing that PDLIM7 and the adaptor APS co-localize with F-actin in insulin-stimulated ruffles established PDLIM7 as a cytoskeletal organizer responsive to growth factor input.

   Evidence Yeast two-hybrid, co-IP in HEK293 cells, immunofluorescence co-localization with F-actin, and mutation analysis

   PMID:15946664

   Open questions at the time

   • Whether PDLIM7-APS regulation of actin is required for insulin signaling outputs was not tested
   • Structural basis for LIM–NPTY interaction unknown
4. 2009 High

   Genetic epistasis in zebrafish revealed that PDLIM7 regulates Tbx5 nuclear–cytoplasmic shuttling and transcriptional output to specify cardiac valve tissue, providing the first in vivo developmental role.

   Evidence Zebrafish morpholino knockdown with analysis of Tbx5 target genes (nppa, tbx2b) and comparison to tbx5 mutant phenotype

   PMID:19895804

   Open questions at the time

   • Molecular mechanism of Tbx5 retention/release by PDLIM7 not defined
   • Whether PDLIM7 shuttles other transcription factors in the heart was unknown
5. 2013 High

   Global knockout in mice confirmed PDLIM7 is essential for postnatal viability, cardiac valve size, and hemostasis, extending its developmental role from fish to mammals and uncovering a platelet/vascular function.

   Evidence Pdlim7-null mice with cardiac morphometry, 3D valve reconstruction, thrombosis assessment, and tail bleed time assays

   PMID:24278323

   Open questions at the time

   • Cell-type-specific contributions (cardiomyocyte vs. platelet vs. smooth muscle) not resolved
   • Molecular targets of PDLIM7 in platelets not identified
6. 2016 Medium

   Silencing in human vascular smooth muscle cells showed that PDLIM7 maintains the contractile differentiated phenotype and cytoskeletal integrity, linking it to vascular disease-relevant biology.

   Evidence siRNA knockdown in cultured SMCs with readouts of SMC marker expression, actin cytoskeleton, and proliferation

   PMID:27470516

   Open questions at the time

   • Downstream signaling pathway connecting PDLIM7 loss to SMC dedifferentiation not mapped
   • In vivo SMC-specific deletion not performed
7. 2020 High

   Identification of PDLIM7 as an E3 ubiquitin ligase for p65, cooperating with PDLIM2 and p62/SQSTM1 for proteasomal degradation, revealed a catalytic function beyond scaffolding and placed PDLIM7 in NF-κB suppression.

   Evidence In vitro and cell-based ubiquitination assays, co-IP for heterodimerization with PDLIM2, double knockdown with cytokine readout, proteasome inhibitor epistasis

   PMID:32849529

   Open questions at the time

   • Catalytic domain or mechanism of E3 ligase activity not structurally defined
   • In vivo inflammatory phenotype of PDLIM7 loss not tested
8. 2023 Medium

   Demonstration that PDLIM7 promotes YAP1 nuclear translocation and that TPM2 competitively blocks this via the PDZ-binding motif revealed PDLIM7 as a regulated switch for Hippo pathway effector localization in cancer.

   Evidence Reciprocal co-IP, competition assays, immunofluorescence, PDZ-binding motif mutations, and xenograft tumor models in prostate cancer cells

   PMID:36823643

   Open questions at the time

   • Mechanism by which PDLIM7 drives YAP1 nuclear import not resolved
   • Generalizability beyond prostate cancer not tested

• The structural basis for PDLIM7's dual scaffold and E3 ligase activities, the identity of additional ubiquitination substrates, and how its cytoskeletal, signaling, and transcriptional functions are coordinated in specific tissues remain unresolved.
• No crystal structure or cryo-EM model of full-length PDLIM7
• Whether E3 ligase activity extends to substrates beyond p65 is unknown
• Tissue-specific conditional knockouts needed to dissect cardiovascular vs. immune functions